Ophthalmology Times Europe October 2021

New strategies are considered for obtaining information from visual assessments while ensuring compliance from paediatric patients.

Results from Phase 3 trials of bispecific antibody faricimab demonstrate that it is more durable than currently available agents, and it has a good safety profile.

There is no significant difference between IOL replacement and rescue in terms of postoperative visual and surgical outcomes for eyes undergoing secondary IOL scleral fixation.

Swept-source optical coherence tomography angiography can detect eyes at risk of developing exudative disease.

Evidence from clinical trials and real-world situations demonstrates the effectiveness and convenience of intraocular drugs to control postoperative inflammation.

Trial results indicate that retinal cell injections improve vision in certain retinitis pigmentosa patients.

Ex vivo experiment identifies potential benefit for supplementary oxygen.